Bausch Health Companies Inc., formerly known as Valeant Pharmaceuticals International, Inc., is a global company that develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products, primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. After a period of significant acquisitions and subsequent challenges, the company rebranded in 2018 to Bausch Health, focusing on innovation and rebuilding its portfolio. It operates through segments including Salix, International, Solta Medical, and a diversified products segment. Bausch Health is committed to providing effective and innovative healthcare solutions to patients and healthcare providers worldwide.
The headquarters serves as the central hub for global operations, strategic decision-making, corporate governance, research and development oversight, and administrative functions for Bausch Health.
The headquarters is situated in a modern office building within a corporate park, reflecting a professional and contemporary business environment. It is equipped with facilities to support its global workforce and operations.
Post-rebranding from Valeant, the work culture at Bausch Health's headquarters is focused on ethical practices, innovation in its core therapeutic areas, and driving sustainable growth. There's an emphasis on collaboration and employee development as the company continues to evolve.
The Laval headquarters is significant as it represents the nerve center of Bausch Health's global activities and is symbolic of its transformation and renewed commitment to healthcare innovation and stakeholder trust.
Bausch Health Companies Inc. maintains a significant global presence, with operations and product distribution spanning North America, Europe, the Middle East, Africa (EMEA), Asia Pacific, and Latin America. Key functions supported globally include research and development, manufacturing, sales and marketing, and distribution of its diverse portfolio of pharmaceutical products (e.g., Salix for gastroenterology, Solta for medical aesthetics), and international pharmaceutical brands. The company strategically manages its operations to cater to regional healthcare needs and market dynamics.
2150 Boulevard Hymus
Laval
Quebec
Canada
Address: 400 Somerset Corporate Blvd, Bridgewater, NJ 08807, USA
The Bridgewater office is crucial for managing Bausch Health's significant presence in the U.S. market, supporting sales, marketing, and distribution of its pharmaceutical and healthcare products across North America.
Address: 1400 N Goodman St, Rochester, NY 14609, USA
Historically a key site for eye health innovation and manufacturing for the broader Bausch legacy. Its current direct role for Bausch Health (post B+L separation) is more nuanced but connects to the company's heritage.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Valeant Pharmaceuticals' leadership includes:
Valeant Pharmaceuticals has been backed by several prominent investors over the years, including:
Bausch Health Companies Inc. has experienced significant leadership renewal over the past 12-18 months, notably with the appointment of a new Chief Executive Officer, Chief Financial Officer, and Chief Human Resources Officer, aiming to steer the company into its next phase of growth and strategic execution.
Discover the tools Valeant Pharmaceuticals uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Bausch Health Companies Inc. commonly uses the 'first.last@bauschhealth.com' email format. Other potential formats might include 'first_initiallast@bauschhealth.com'. For effective communication, verifying the exact format or using professional networking platforms is recommended.
first.last@bauschhealth.com
Format
thomas.appio@bauschhealth.com
Example
85%
Success rate
Yahoo Finance / Bausch Health • May 7, 2024
Bausch Health reported its Q1 2024 financial results, highlighting revenue growth driven by its Salix and International segments. The company reaffirmed its full-year 2024 financial guidance, indicating steady performance and strategic execution....more
GlobeNewswire / Bausch Health • February 21, 2024
Bausch Health released its fourth-quarter and full-year 2023 financial results, detailing revenue performance across its segments and outlining key achievements and strategic priorities for the company looking forward....more
Bausch Health Press Release • August 1, 2023
Bausch Health announced the appointment of Seana Carson as Senior Vice President and Chief Human Resources Officer, effective August 1, 2023. Ms. Carson brings extensive experience in human resources leadership within the healthcare industry....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Valeant Pharmaceuticals, are just a search away.